A window on reality?

[1]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[2]  C. Stewart,et al.  Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Link,et al.  Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. , 2001, Medical and pediatric oncology.

[4]  W. Meyer,et al.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Harris,et al.  #465 Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group (POG) phase II study , 1999 .

[6]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Kaufmann,et al.  Topotecan in combination chemotherapy. , 1997, Seminars in oncology.

[8]  L Bomgaars,et al.  The development of camptothecin analogs in childhood cancers. , 2001, The oncologist.

[9]  J. Kurtzberg,et al.  Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.

[10]  P. Houghton,et al.  Clinical use of topoisomerase I inhibitors in anticancer treatment. , 2000, Medical and pediatric oncology.

[11]  M. Smith,et al.  Phase II window studies: 10 years of experience and counting. , 2001, Journal of pediatric hematology/oncology.

[12]  M. Bernstein,et al.  Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.